Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Top Cited Papers
Open Access
- 14 May 2015
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 372 (20), 1909-1919
- https://doi.org/10.1056/nejmoa1414325
Abstract
Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology–Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.)Keywords
This publication has 13 references indexed in Scilit:
- Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse modelsOncology Reports, 2014
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Use of Statins and the Risk of Death in Patients With Prostate CancerJournal of Clinical Oncology, 2014
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialThe Lancet Oncology, 2012
- Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumoursBritish Journal of Cancer, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumorsInvestigational New Drugs, 2008
- Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid TumorsCancer Investigation, 2008
- Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumorsCancer, 2006
- Systemic Therapy for Colorectal CancerThe New England Journal of Medicine, 2005